Neuraptive Therapeutics

Neuraptive Therapeutics Earns FDA Orphan Drug Designation for Novel Peripheral Nerve Injury Treatment

WAYNE, PA — Neuraptive Therapeutics Inc. recently announced that its novel treatment for peripheral nerve injury, NTX-001, has received Orphan Drug Designation from the United States Food and Drug Administration …

Neuraptive Therapeutics Earns FDA Orphan Drug Designation for Novel Peripheral Nerve Injury Treatment Read More
NRx Pharmaceuticals

NRx Pharmaceuticals’ NRX-101 Receives FDA Fast Track Designation: A Potential Gamechanger for Treating Complex UTIs

RADNOR, PA — In a significant development that could revolutionize the treatment of complicated urinary tract infections (cUTI) and pyelonephritis, NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) has received Qualified Infectious Disease …

NRx Pharmaceuticals’ NRX-101 Receives FDA Fast Track Designation: A Potential Gamechanger for Treating Complex UTIs Read More
Food and Drug Administration

FDA’s Week of Innovation: Scallops Alert, AI Health Challenge Winners, Digital Health Equity & Novel Drug Approvals

WASHINGTON, D.C. — In a series of announcements last week, the U.S. Food and Drug Administration (FDA) showcased its broad range of responsibilities, from food safety to advancing medical technology …

FDA’s Week of Innovation: Scallops Alert, AI Health Challenge Winners, Digital Health Equity & Novel Drug Approvals Read More